PARSIPPANY, N.J., Sept. 27, 2006 (PRIMEZONE) -- Alteon Inc. (AMEX:ALT) announced today that a Phase 2 clinical study of alagebrium, a novel Advanced Glycation End-product (A.G.E.) breaker, will be conducted at the University of Texas Southwestern Medical Center at Dallas as part of a five-year $3.1 million National Institutes of Health (NIH) grant. alagebrium will be studied as a novel intervention when combined with exercise training with the goal of significantly improving cardiac compliance and diastolic function in aged individuals. Demonstrating an ability of alagebrium to reverse deficits attributable to aging and sedentary lifestyle would be supportive of Alteon’s development efforts for alagebrium in diastolic heart failure (DHF).
